RxDoctor Payments Data

Brett Brimhall, MD

Ophthalmology · Las Vegas, NVNPI 1033191853

Payments from drug & device makers

$1,542in general payments, 2019–2025

Across 61 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$614
  • Ivantis, Inc$172
  • AbbVie$132
  • Johnson & Johnson Surgical Vision, Inc.$130
  • Sight Sciences, Inc.$94
  • NEW World Medical,inc.$81
  • plus $320 from 12 others

What the payments were for

  • Food & beverage$1,50397%
  • Education$91%
  • Entertainment$312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,542 in reported general payments places this provider in the 45th percentile of 121 ophthalmology providers in Nevada.

See all ophthalmology providers in Nevada

Medicare billing

Part B allowed, 2024
$554,527
Medicare patients
1,017
Services billed
5,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine15$20,907
LumiganBimatoprost37$17,819
XiidraLifitegrast15$13,964
RhopressaNetarsudil Mesylate18$8,425
SimbrinzaBrinzolamide/Brimonidine Tart11$5,946
Latanoprost361$3,516
Travoprost13$3,250
Prednisolone Acetate84$2,743
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat110$2,690
MoxifloxacinMoxifloxacin Hcl43$917
Ketorolac Tromethamine29$759
Doxycycline Hyclate19$659
Brimonidine Tartrate26$637
Timolol Maleate31$550
ErythromycinErythromycin Base47$374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$132$38,72752 claims
AlconSimbrinza$614$5,94611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 121 ophthalmology providers in Nevada.

Other ophthalmology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →